GSK Arexvy recommended for adults aged 50-59 at increased risk for severe RSV disease by US Advisory Committee on Immunization Practices Ruchika Sharma20 April 2025 9:00 AM ISTGSK plc has announced that the Advisory Committee on Immunization Practices (ACIP) voted in favour of recommending the use of RSV vaccines including...
Moderna's Q4 Revenue Falls 66% to USD 966M Amid COVID Vaccine Sales Slump Farhat Nasim16 Feb 2025 9:30 AM ISTBengaluru: Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down manufacturing amid...
Setback for Moderna: USFDA Halts Norovirus Vaccine Trial After Guillain-Barre Syndrome Case Farhat Nasim15 Feb 2025 3:25 PM ISTBengaluru: Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a rare...
Medical Bulletin 13/ November/ 2024 Dr. Bhumika Maikhuri13 Nov 2024 3:00 PM ISTHere are the top medical news for the day:Can Heart Medicine Lead to Depression?All patients who have had a heart attack are typically treated using...
Researchers Highlight the Best Time for RSV Vaccine During Pregnancy Dr. Bhumika Maikhuri13 Nov 2024 8:30 AM ISTCurrent guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV)-which typically causes mild, cold-like...
Pfizer RSV Vaccine Abrysvo gets USFDA ok for high-risk adults aged 18-59 MD Bureau23 Oct 2024 2:37 PM ISTThe approval for the vaccine, Abrysvo, in adults aged 18 to 59 was based on the results from a late stage trial in which two doses of the vaccine were...
Medical Bulletin 21/ October/ 2024 Dr. Bhumika Maikhuri21 Oct 2024 3:00 PM ISTHere are the top medical news for the day:Innovative Surgical Techniques Used in World’s First Combined Face and Whole-Eye TransplantationAn...
Approximately 80 Percent Protection May be Provided by RSV Vaccine Against Severe Disease and Death: Study Suggests Dr. Bhumika Maikhuri21 Oct 2024 8:15 AM ISTA multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the respiratory syncytial virus...
GSK alleges patent infringement by Moderna in development of COVID19, RSV vaccines, files lawsuit MD Bureau16 Oct 2024 3:51 PM ISTLondon: British drugmaker GlaxoSmithKline (GSK) sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of violating...
Pfizer wins bid to invalidate 2 GSK patents relating to RSV vaccine Ruchika Sharma9 Oct 2024 2:33 PM ISTLondon: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held by GlaxoSmithKline (GSK)...
Moderna forecasts lower sales next year, shares near four-year low MD Bureau Team14 Sept 2024 11:34 AM ISTLondon: Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key products and predicted...
New RSV vaccine can result in individual and societal cost savings, benefits for elderly: Study Dr. Kamal Kant Kohli6 Sept 2024 8:30 PM ISTVaccination against respiratory syncytial virus for adults over 60 is likely cost-effective by preventing illness, hospitalizations, lost quality of...
